132 related articles for article (PubMed ID: 8282540)
1. Control of IgE responses. II. Isotype specific suppression of peak hapten specific IgE antibody forming cell responses in BPO-KLH sensitized mice after oral administration of muramyldipeptide or murabutide.
Auci DL; Chice SM; Dukor P; Durkin HG
Immunopharmacology; 1993; 26(2):157-69. PubMed ID: 8282540
[TBL] [Abstract][Full Text] [Related]
2. Control of IgE responses. 4. Isotype-specific suppression of peak BPO-specific IgE antibody-forming cell responses and of BPO-specific IgE in serum by muramyldipeptide or murabutide after administration to mice by gavage.
Auci DL; Carucci JA; Chice SM; Smith MC; Dukor P; Durkin HG
Int Arch Allergy Immunol; 1993; 101(2):167-76. PubMed ID: 8508053
[TBL] [Abstract][Full Text] [Related]
3. Control of IgE responses. V. Oral administration of a synthetic derivative of the inner bacterial cell wall (SDZ 280.636) to sensitized mice induces isotype specific suppression of peak hapten specific IgE antibody forming cell responses, serum IgE levels and immediate hypersensitivity responses.
Auci DL; Kleiner GI; Chice SM; Athanassiades TJ; Dukor P; Durkin HG
Immunol Invest; 1998; 27(1-2):105-20. PubMed ID: 9561922
[TBL] [Abstract][Full Text] [Related]
4. IL-6 mediated isotype specific suppression of hapten specific IgE in serum of BPO-KLH sensitized mice: role of IFN alpha in maintainance of hapten specific IgE responses.
Auci DL; Miller H; Chice SM; Durkin HG
Immunol Invest; 1994 Apr; 23(3):213-21. PubMed ID: 8070849
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptide-mediated regulation of hapten-specific IgE responses in mice. II. Mechanisms of substance P-mediated isotype-specific suppression of BPO-specific IgE antibody-forming cell responses induced in vitro.
Carucci JA; Herrick CA; Durkin HG
J Neuroimmunol; 1994 Jan; 49(1-2):89-95. PubMed ID: 7507499
[TBL] [Abstract][Full Text] [Related]
6. Peyer's patches and mesenteric lymph nodes are the sites of first appearance of IgE bearing B lymphocytes and hapten specific IgE antibody forming cells in BPO-KLH sensitized mice.
Auci DL; Chice SM; Heusser C; Athanassiades TJ; Durkin HG
Reg Immunol; 1992; 4(4):216-24. PubMed ID: 1476874
[TBL] [Abstract][Full Text] [Related]
7. Cytokine-induced suppression and potentiation of hapten-specific immediate hypersensitivity responses.
Auci DL; Kleiner G; Sheikh A; Acosta E; Athanassiadies TJ; Murali MR; Durkin HG
Immunol Invest; 1993 Apr; 22(3):205-18. PubMed ID: 7685321
[TBL] [Abstract][Full Text] [Related]
8. Control of IgE responses. III. IL-6 and IFN-alpha are isotype-specific regulators of peak BPO-specific IgE antibody-forming cell responses in mice.
Auci DL; Kleiner GI; Chice SM; Dukor P; Durkin HG
Clin Immunol Immunopathol; 1993 Mar; 66(3):219-24. PubMed ID: 8432046
[TBL] [Abstract][Full Text] [Related]
9. An in vitro murine model of a penicillin specific IgE anamnestic response.
Smith MC; Heusser C; Wagner K; Blaser K; Durkin HG
J Immunol Methods; 1990 Jul; 131(1):55-64. PubMed ID: 2380568
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptide-mediated regulation of hapten-specific IgE responses in mice. I. Substance P-mediated isotype-specific suppression of BPO-specific IgE antibody-forming cell responses induced in vivo and in vitro.
Carucci JA; Auci DL; Herrick CA; Durkin HG
J Leukoc Biol; 1995 Jan; 57(1):110-5. PubMed ID: 7530276
[TBL] [Abstract][Full Text] [Related]
11. Origin and fate of IgE-bearing lymphocytes. II. Gut-associated lymphoid tissue as sites of first appearance of IgE-bearing B lymphocytes and hapten-specific IgE antibody-forming cells in mice immunized with benzylpenicilloyl-keyhole limpet hemocyanin by various routes: relation to asialo GM1 ganglioside+ cells and IgE/CD23 immune complexes.
Auci DL; Chice SM; Heusser C; Athanassiades TJ; Durkin HG
J Immunol; 1992 Oct; 149(7):2241-8. PubMed ID: 1388186
[TBL] [Abstract][Full Text] [Related]
12. Regulation of hapten-specific memory IgE responses induced in vitro. Requirement for both Thy-1+ AsGM1+ and Thy-1+ AsGM1- cells and for IFN-alpha and IL-4.
Herrick CA; Carucci JA; Kleiner GI; Durkin HG
J Immunol; 1993 Oct; 151(7):3440-9. PubMed ID: 8104220
[TBL] [Abstract][Full Text] [Related]
13. Tetracycline-mediated IgE isotype-specific suppression of ongoing human and murine IgE responses in vivo and murine memory IgE responses induced in vitro.
Joks R; Smith-Norowitz T; Nowakowski M; Bluth MH; Durkin HG
Int Immunol; 2010 Apr; 22(4):281-8. PubMed ID: 20181654
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a memory in vitro murine IgE response to benzylpenicillin and its resistance to suppression by anti-IL-4 antibody.
Heusser CH; Wagner K; Brinkmann V; Severinson E; Blaser K
Int Arch Allergy Appl Immunol; 1989; 90 Suppl 1():45-50. PubMed ID: 2613352
[TBL] [Abstract][Full Text] [Related]
15. IFN-alpha-mediated suppression of low-affinity FC(epsilon) receptors on Peyer's patch lymphocytes and augmentation of soluble CD23: implications for IgE responses.
Miller H; Bluth MH; Chice SM; Durkin HG; Auci DL
J Leukoc Biol; 1996 May; 59(5):725-7. PubMed ID: 8656058
[TBL] [Abstract][Full Text] [Related]
16. In vivo effects of ovalbumin-conjugated muramyl peptides on the anti-ovalbumin IgE and IgG responses in mice.
Prouvost-Danon A; Bahr GM; Chedid L; Ekwalanga M; Bassot S
Int J Immunopharmacol; 1984; 6(5):425-31. PubMed ID: 6500780
[TBL] [Abstract][Full Text] [Related]
17. The development of IgE+ memory B cells following primary IgE immune responses.
Le Gros G; Schultze N; Walti S; Einsle K; Finkelman F; Kosco-Vilbois MH; Heusser C
Eur J Immunol; 1996 Dec; 26(12):3042-7. PubMed ID: 8977302
[TBL] [Abstract][Full Text] [Related]
18. Suppression of the benzylpenicilloyl- (BPO) specific IgE formation with isologous anti-idiotypic antibodies in BALB/c mice.
Blaser K; Nakagawa T; de Weck AL
J Immunol; 1980 Jul; 125(1):24-30. PubMed ID: 7381201
[TBL] [Abstract][Full Text] [Related]
19. Induction of immunological tolerance to the penicilloyl antigenic determinant. III. Suppression of benzylpenicilloyl-specific IgE antibody formation by cleavable penicilloylated dextran.
Nakagawa T; Otz U; de Weck AL; Schneider CH
Int Arch Allergy Appl Immunol; 1981; 64(2):210-6. PubMed ID: 6161899
[TBL] [Abstract][Full Text] [Related]
20. The introduction of one or two 3 beta-cholestanyl residues into benzylpenicilloyl-eicosa-L-lysines greatly potentiates their tolerogenicity for anti-benzylpenicillol IgE antibody formation.
Lüscher IF; Weber E; de Weck AL
Eur J Immunol; 1984 Jan; 14(1):68-74. PubMed ID: 6229410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
